marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2022-Q1
added 12-23-2023
Genocea Biosciences Balance Sheet 2011-2024 | GNCA
Annual Balance Sheet Genocea Biosciences
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-30.7 M | -64.3 M | -25.7 M | -11.5 M | 2.04 M | -10.5 M | 76.3 M | 18.5 M | -2.41 M | -7.47 M | -5.54 M |
Long Term Debt |
4.15 M | 13.9 M | 13.4 M | 9.56 M | 7.65 M | 13.8 M | 16.5 M | 11.5 M | 8.93 M | 2.37 M | 51 K |
Long Term Debt Current |
2.35 M | 1.59 M | 990 K | 5.26 M | 6.66 M | 3.15 M | - | - | - | - | - |
Total Non Current Liabilities |
- | 64.5 M | 21.3 M | 13 M | 7.76 M | 14 M | 16.5 M | 12.1 M | 9.84 M | 3.02 M | 390 K |
Total Current Liabilities |
18.7 M | 25 M | 6.28 M | 10.7 M | 15.8 M | 10.4 M | 5.97 M | 5.84 M | - | - | - |
Total Liabilities |
28.9 M | 89.5 M | 27.6 M | 23.8 M | 23.5 M | 24.4 M | 22.5 M | 17.9 M | 14.3 M | 7.23 M | 2.65 M |
Deferred Revenue |
1.7 M | 1.64 M | - | - | - | - | 235 K | 555 K | 12 K | - | 23 K |
Retained Earnings |
-408 M | -375 M | -331 M | -292 M | -264 M | -207 M | -158 M | -115 M | -80.1 M | -58.4 M | -43.6 M |
Total Assets |
56 M | 98.5 M | 52.6 M | 31.1 M | 17.5 M | 69.9 M | 112 M | 50.4 M | 15.8 M | 13.5 M | 6.94 M |
Cash and Cash Equivalents |
37.1 M | 79.8 M | 40.1 M | 26.4 M | 12.3 M | 27.4 M | 17.3 M | 20.1 M | 12.2 M | 11.5 M | - |
Book Value |
27.1 M | 8.98 M | 25 M | 7.34 M | -6.05 M | 45.5 M | 89.7 M | 32.5 M | 1.43 M | 6.3 M | 4.29 M |
Total Shareholders Equity |
27.1 M | 8.98 M | 25 M | 7.34 M | -6.05 M | 45.5 M | 89.7 M | 32.5 M | -80.1 M | -58.4 M | - |
All numbers in USD currency
Quarterly Balance Sheet Genocea Biosciences
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | 2.95 M | 4.15 M | 5.33 M | 6.49 M | 7.65 M | - | - | - | 5.82 M | 13.4 M | 13.4 M | 13.4 M | 13.4 M | 9.56 M | 9.56 M | 9.56 M | 9.56 M | 7.65 M | 7.65 M | 7.65 M | 7.65 M | 13.8 M | 13.8 M | 13.8 M | 13.8 M | 16.5 M | 16.5 M | 16.5 M | 16.5 M | 11.4 M | 11.4 M | 11.4 M | 11.5 M | 8.93 M | 8.93 M | 8.93 M | 8.93 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
- | - | - | 26.4 M | 28.9 M | 27.1 M | 73.3 M | 82.2 M | 89.5 M | 86 M | 89.5 M | 32.2 M | 27.6 M | 27.6 M | 27.6 M | 27.6 M | 23.8 M | 23.8 M | 23.8 M | 23.8 M | 23.5 M | 23.5 M | 23.5 M | 23.5 M | 24.4 M | 24.4 M | 24.4 M | 24.4 M | 22.5 M | 22.5 M | 22.5 M | 22.5 M | 17.8 M | 17.8 M | 17.8 M | 17.9 M | 14.3 M | 14.3 M | 14.3 M | 14.3 M | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | 1.56 M | 1.7 M | - | 1.64 M | 1.64 M | 1.64 M | 1.64 M | 1.64 M | 1.64 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 235 K | 235 K | 235 K | 235 K | 555 K | 555 K | 555 K | 555 K | 12 K | 12 K | 12 K | 12 K | - | - | - | - | - | - | - | - |
Retained Earnings |
- | - | - | -424 M | -408 M | -395 M | -391 M | -387 M | -375 M | -360 M | -375 M | -344 M | -331 M | -331 M | -331 M | -331 M | -292 M | -292 M | -292 M | -292 M | -264 M | -264 M | -264 M | -264 M | -207 M | -207 M | -207 M | -207 M | -158 M | -158 M | -158 M | -158 M | -115 M | -115 M | -115 M | -115 M | -80.1 M | -80.1 M | -80.1 M | -80.1 M | - | - | - | - | - | - | - | - |
Total Assets |
- | - | - | 38.8 M | 56 M | 64.9 M | 77.4 M | 83.9 M | 98.5 M | 106 M | 98.5 M | 45.2 M | 52.6 M | 52.6 M | 52.6 M | 52.6 M | 31.1 M | 31.1 M | 31.1 M | 31.1 M | 17.5 M | 17.5 M | 17.5 M | 17.5 M | 69.9 M | 69.9 M | 69.9 M | 69.9 M | 112 M | 112 M | 112 M | 112 M | 50.3 M | 50.3 M | 50.3 M | 50.4 M | 15.8 M | 15.8 M | 15.8 M | 15.8 M | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
- | - | - | 20.1 M | 37.1 M | 48.9 M | 60.4 M | 66 M | 79.8 M | 79.8 M | 79.8 M | 79.8 M | 40.1 M | 40.1 M | 40.1 M | 40.1 M | 26.4 M | 26.4 M | 26.4 M | 26.4 M | 12.3 M | 12.3 M | 12.3 M | 12.3 M | 27.4 M | 27.4 M | 27.4 M | 27.4 M | 17.3 M | 17.3 M | 17.3 M | 17.3 M | 20.1 M | 20.1 M | 20.1 M | 20.1 M | 12.2 M | 12.2 M | 12.2 M | 12.2 M | 11.5 M | - | - | - | 5.74 M | - | - | - |
Book Value |
- | - | - | 12.4 M | 27.1 M | 37.8 M | 4.06 M | 1.76 M | 8.98 M | 20.2 M | 8.98 M | 13 M | 25 M | 25 M | 25 M | 25 M | 7.34 M | 7.34 M | 7.34 M | 7.34 M | -6.05 M | -6.05 M | -6.05 M | -6.05 M | 45.5 M | 45.5 M | 45.5 M | 45.5 M | 89.7 M | 89.7 M | 89.7 M | 89.7 M | 32.5 M | 32.5 M | 32.5 M | 32.5 M | 1.43 M | 1.43 M | 1.43 M | 1.43 M | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
- | - | - | 12.4 M | 27.1 M | 37.8 M | 4.06 M | 1.76 M | 8.98 M | 20.2 M | 8.98 M | 8.98 M | 25 M | 31.4 M | 25 M | 25 M | 7.34 M | 7.34 M | 7.34 M | 7.34 M | -6.05 M | -6.05 M | -6.05 M | -6.05 M | 45.5 M | 45.5 M | 45.5 M | 45.5 M | 89.7 M | 89.7 M | 89.7 M | 89.7 M | 32.5 M | 32.5 M | 32.5 M | 32.5 M | -80.1 M | -80.1 M | -80.1 M | -80.1 M | -58.4 M | - | - | - | -43.6 M | - | - | - |
All numbers in USD currency